Loading...
Loading...
India's cetuximab imports from CHINA total $145 across 1 shipments from 1 foreign suppliers. PIERCE BIOTECHNOLOGY,INC. leads with $145 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for cetuximab — a concentrated sourcing relationship with select suppliers from CHINA.

PIERCE BIOTECHNOLOGY,INC. is the leading Cetuximab supplier from CHINA to India, with import value of $145 across 1 shipments. The top 5 suppliers — PIERCE BIOTECHNOLOGY,INC. — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PIERCE BIOTECHNOLOGY,INC. | $145 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED | $145 | 1 | 100.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Cetuximab suppliers from CHINA to India include PIERCE BIOTECHNOLOGY,INC.. The leading supplier is PIERCE BIOTECHNOLOGY,INC. with import value of $145 USD across 1 shipments. India imported Cetuximab worth $145 USD from CHINA in total across 1 shipments.
India imported Cetuximab worth $145 USD from CHINA across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Cetuximab sourced from CHINA include INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED. The largest buyer is INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED with $145 in imports across 1 shipments.
The total value of Cetuximab imports from CHINA to India is $145 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists